Single dose of Oxford vaccine can cut COVID-19 transmission risk by 67 percent, study indicates

Multiple countries have advised against administering the Oxford-AstraZeneca vaccine to the elderly population.

Agence France-Presse February 03, 2021 18:12:46 IST
Single dose of Oxford vaccine can cut COVID-19 transmission risk by 67 percent, study indicates

Representational image of a COVID-19 vaccine candidate. Image: Imperial College London via AP

The Oxford-AstraZeneca vaccine significantly reduces virus transmission and is highly protective after a single dose, according to an Oxford University study, which the British government said Wednesday vindicated its inoculation strategy. "It does show the world that the Oxford jab works, it works well," Health Secretary Matt Hancock told BBC Radio, hailing the study's findings as "good news". "It slows transmission by around two-thirds, so it categorically supports the strategy that we're undertaking," Hancock said.

The study's findings came amid much debate over the effectiveness of the AstraZeneca jab among the elderly.

Although the European Medicines Agency recommended it for adults of all ages last week, several countries have advised against administering the AstraZeneca jab to older people.

Germany has already said it will not advise over 65s to get it.

Italy's medicines agency on Saturday approved the vaccine for all adults but recommended alternatives for people aged over 55.

And French President Emmanuel Macron last week said the Oxford-AstraZeneca vaccine was "quasi-ineffective" for those over 65.

The UK has been under lockdown since December with schools closed and no definite end-date, although a review of the situation is expected in mid-February. The country has had 3.8 million cases and 1,08,013 deaths.

The Oxford study, which is awaiting peer review, found that those who had been vaccinated with a single dose of the vaccine were 67 percent less likely to test positive with a PCR test, "suggesting the potential for a substantial reduction in transmission".

Dosing schedule

It also provided backing for the UK's strategy of administering as many first doses of vaccine to high-risk groups as possible and allowing a 12-week interval before the second dose, which has been criticised by some experts.

The other vaccine already being rolled out in the UK, the Pfizer-BioNTech, was designed to be administered with a shorter interval.

"We are confident that the 12-week dosing schedule is the right one for both of the vaccines that we're using in the UK," Hancock said Wednesday.

Researchers found that a single dose was 76 percent effective in preventing virus symptoms after 22 days and for up to 90 days, while it did not prevent asymptomatic illness.

It was more effective to wait 90 days than to administer the second dose, researchers found "providing further support for current policy".

The vaccine is cheap to produce and is being sold at cost price. It can also be stored at fridge temperature, while the Pfizer vaccine requires extremely cold storage.

The survey had 17,177 participants in Britain, Brazil and South Africa. The data covers the period up to December 7, 2020. None of those studied were hospitalised.

The vaccine invented by scientists at the University of Oxford is being developed and manufactured by AstraZeneca.

Updated Date:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Asian, African nations urge vaccine makers to share blueprints, COVID-19 vaccine know-how
World

Asian, African nations urge vaccine makers to share blueprints, COVID-19 vaccine know-how

Companies traditionally pour huge amounts of money and research into drugs and vaccines, for the right to profit from them.

India's first vaccine shipment under COVAX likely this week, says Soumya Swaminathan
Health

India's first vaccine shipment under COVAX likely this week, says Soumya Swaminathan

The first shipment from India, from the Serum Institute, will be going out to at least 25 or 30 countries, said the WHO chief scientist

Serum Institute writes to PMO seeking reforms in drug regulations for non-COVID vaccines
India

Serum Institute writes to PMO seeking reforms in drug regulations for non-COVID vaccines

Manufacture and stockpile of Covishield doses during the clinical trial helped bring the vaccine out quicker, protecting millions of lives, the letter said.